6-thioguanine (6-TGN) and 6-methylmercaptopurine (6-MMP). These metabolites, rather than the absolute dose of AZA, are associated with clinical efficacy and toxicity. An idiosyncratic skewed metabolism towards 6-MMP in some patients ("shunters") increases the risk of hepatotoxicity and treatment failure. Allopurinol can correct such shunts 1 . Therapeutic protocols using metabolite concentrations have been shown to be cost effective, improve efficacy, and decrease treatment morbidity in IBD 1 . Only one small study estimated a therapeutic 6-TGN level for SLE patients 2 . There are scant data on AZA shunters in connective tissue disease 3 . Objectives: Explore the proportion of AZA therapeutic failure, toxicity, and shunters in CTD patients. Methods: Retrospective, multicentre audit of AZA metabolite levels in CTD patients from 2012-2016. Patient demographics, treatments, disease activity and drug toxicity were also extracted. Results: 61 testing episodes occurred in 34 patients whose mean age was 55 (32-79) years; predominantly female (N=26, 77%), with SLE (N=19, 56%). Active disease was present in 15/61 (25%) episodes. 20/34 (60%) patients were on HCQ + AZA. 25/34 (76%) of patients were either on no or <10mg/day of prednisone. 22/61 (36%) episodes had bone marrow suppression, and 8/61 (13%) had moderate liver function derangement. 12/35 (34%) patients were AZA shunters. Based on AZA metabolite levels, patients were classified into four categories: 
SLE patients were over-represented in the underdosed/non-compliant category (7/9). Patients in underdosed and 6-MMP shunter categories had more active disease (44% & 31%), compared with appropriate and overdosed (17% and 19% p=0.24) . Surprisingly, patients who were overdosed by 6TGN levels had the lowest mean AZA dose. 6-MMP shunters had significantly lower median 6TGN levels (147pmol/8x10 8 RBC), yet toxic MMP levels (9630pmol/8x10 8 RBC) that was associated with worst LFT derangement prevalence (4/13, 31% vs <13%, p=0.16). Conclusions: AZA dose is poorly predictive of 6-TGN and 6-MMP levels. Overall, one third of CTD patients were shunters, with lower 6-TGN levels and more hepatotoxicity. Only 40% of test episodes were appropriately dosed. Patients with low disease activity are more likely to have adequate 6TGN levels, however, 40% of patients with CTD won't have adequate disease control despite therapeutic 6-TGN levels. AZA metabolites can identify the multiple causes for therapeutic failure (under dosing, shunter, or true non-response), and enable early detection of shunters to avoid liver toxicity. Background: Hydroxychloroquine (HCQ) are considered to be effective against cutaneous lupus erythematosus (CLE) and symptoms associated with systemic lupus erythematosus (SLE) such as rashes, joint pain, and fatigue. In a randomized controlled trial in stable active patients with SLE on HCQ treatment, those who achieved blood HCQ levels greater than or equal to 1000ng/ml had a tendency for reduced SLE flares during a 7 month period [1] . To prevent ocular toxicity, HCQ should be maintained at a dose of 6.5mg/kg or less for ideal body weight [2], however, optimal HCQ dosage is unclear. Objectives: To extract the problem of the dosage based on ideal body weight and identify safer and more effective HCQ dosage. Methods: We enrolled patients who took HCQ for SLE or CLE more than 3 months in our institute and 2 related facilities from September 2015. We used Cutaneous Lupus Erythematous Disease Area and Severity Index (CLASI) to evaluate cutaneous symptoms and evaluated effect at start of administration and 3 months of that. The attending doctors assessed the adverse events (AEs). We investigated the change of serum biomarker, such as the value of serum complement and anti-ds-DNA body, the number of white blood cells, lymphocytes and platelets. Results: We enrolled the 30 patients with administration of HCQ more than 3 months and in CLE were 2 cases, in SLE were 28 cases. In 21 cases HCQ dosage were based on ideal weight. The AEs were in 13/30 cases (43.3%). The AEs were the new cutaneous symptoms in 5 cases, eye manifestation in 3 cases (abnormal visual field in 2 cases, color anomaly in 1 case), diarrhea in 2 cases, fever in 2 cases, feeling of fatigue in 2 cases, renal dysfunction in 1 case, muscular pain in 1 case, and pericarditis in 1 case. The eye manifestation in the 3 cases disappeared for a few days by stopping or reducing HCQ dosage. Although we needed glucocorticoid treatment for pericarditis, the other AEs improved by reducing HCQ dosage or stopping. The AEs of taking HCQ 200mg/day were in 6 cases, 200mg and 400mg alternatively on every other day in 6 cases, and 400mg/day in 1 case. The AEs of taking HCQ dosage based on ideal body weight were in 10/21 cases (47.6%) and by minimal dosage in 3/9 cases (33.3%). 22/28 cases (78.6%) significant improved cutaneous symptoms (amount of mean change of CLASI -4.57, p=0.024). There is no difference in the efficacy of cutaneous symptoms between group received HCQ based on ideal body weight (80.0%) and the others (92.3%). 5/21 cases of HCQ based on ideal body weight were made to reduce HCQ dosage due to AEs, but all 5 cases improved cutaneous symptoms. 53.3% (16/30) cases increased complement, but other biomarkers didn't change. Conclusions: HCQ was effective for the treatment of CLE even when HCQ dosage was reduced due to AEs. These findings suggest that low-dose HCQ is also effective and safe, and HCQ initial dosage wasn't the need to adjust for ideal body weight. Objectives: We undertook this study to summarize the body of evidence available from published clinical trials on the effectiveness of omega-3 fatty acids on clinical and laboratory outcomes in SLE. Methods: Two independent reviewers systematically searched PubMed, MED-LINE, Scopus, and the reference lists of related articles for studies published from inception to November 2016 using relevant keywords. Randomized, controlled trials (RCTs) on SLE patients comparing omega-3 fatty acids with placebo were included in the analysis. The quality of the included RCTs was assessed in accordance with the Cochrane Handbook. A random effects model was used to pool extracted data. Heterogeneity was evaluated with Chi 2 test and I 2 , with p-values <0.05 considered significant. Data presented in median and interquartile range were converted to mean and standard deviation using the method described by Wan et al. Results: A total of seven clinical trials consisting of 303 subjects with a duration of treatment ranging from 12 to 52 weeks were included. In studies using SLAM-R as the measurement of disease activity (n=82), there was a statistically significant mean score reduction in the omega-3 fatty acid group vs. the placebo group at 24 weeks. However, in studies that used mean change in SELENA-SLEDAI (n=117, WMD: -0.87, 95% CI: -3.9, 2.17, I 2 =0%, p=0.58) and PGA (n=117, WMD -0.46, 95% CI: -1.16, 0.24, I
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2 =85%, p=0.20) scores, there was no significant effect ( Figure 1 ). Mean brachial artery diameter after 12 weeks likewise did not reveal
